Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Symptoms from oral supplementation alone are exceedingly rare because the body absorbs so little at high doses
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, end points/outcomes of interest, statistical analysis plan, data requirements, publication plan and qualifications of the researcher(s)
Our medical team can help you understand the compliance considerations for your specific situation
Phase 2 study of AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) in patients with end stage renal disease (ESRD) undergoing hemodialysis (HD)
US$ 29.25
US$ 21.35
US$ 23.30
US$ 28.18
US$ 20.32
US$ 22.55
